XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Inclusion Criteria

• •Histologically confirmed diagnosis of a primary malignant glioma.
• •Symptomatic peritumoral brain edema requiring initiation or increase of dexamethasone treatment.
• •If a patient is on dexamethasone for treatment of symptomatic peritumoral brain edema, the dose must be stable and should not exceed 24mg/dl for a minimum of 7 days prior to Baseline.
• •Presence of peritumoral brain edema confirmed by MRI scan or comparable diagnostic technology obtained within 21 days of Baseline.
• •Capable of self-administration of subcutaneous injections twice daily for 8 weeks or availability of assistance from caregiver.